Effect of Body Composition Change during Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma

被引:5
作者
Onishi, Sachiyo [1 ]
Tajika, Masahiro [1 ]
Tanaka, Tsutomu [1 ]
Yamada, Keisaku [1 ]
Kamiya, Tomoyasu [1 ]
Abe, Tetsuya [2 ]
Higaki, Eiji [2 ]
Fujieda, Hironori [2 ]
Nagao, Takuya [2 ]
Inaba, Yoshitaka [3 ]
Muro, Kei [4 ]
Shimizu, Masahito [5 ]
Niwa, Yasumasa [1 ]
机构
[1] Aichi Canc Ctr Hosp, Dept Endoscopy, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[2] Aichi Canc Ctr Hosp, Dept Surg Gastroenterol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[3] Aichi Canc Ctr Hosp, Dept Diagnost & Intervent Radiol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[4] Aichi Canc Ctr Hosp, Dept Clin Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan
[5] Gifu Univ, Grad Sch Med, Dept Gastroenterol Internal Med, 1-1 Yanagido, Gifu 5011194, Japan
关键词
esophageal squamous cell carcinoma; neoadjuvant chemotherapy; sarcopenia; SKELETAL-MUSCLE MASS; PULMONARY COMPLICATIONS; PSOAS MUSCLE; SARCOPENIA; CANCER; OUTCOMES; PREDICTOR; NUTRITION; MORTALITY; IMPACT;
D O I
10.3390/jcm11030508
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Effects of changes in body composition during neoadjuvant chemotherapy (NAC) on perioperative complications and prognosis are unknown in patients with esophageal squamous cell carcinoma (ESCC). A total of 175 patients who underwent surgery for ESCC in our hospital between 2016 and 2019 were examined. The psoas muscle index (PMI) was calculated from the total psoas muscle area, and the visceral fat mass (VFM) at the umbilical level was measured. We defined body composition change (BCC) group as those with increased VFM of >= 3% and decreased PMI of >= 3% during NAC. Sarcopenia (S) was defined as PMI < 5.89 (male) and <4.06 (female). Nutritional assessment using the Subjective Global Assessment tool was performed upon admission. The percentages of BCC group, pre-NAC S, and post-NAC S was 32.5%, 79.4%, and 80.0%, respectively. BCC group had significantly more postoperative complications (p < 0.01) and longer hospital stays (p = 0.03) than groups pre-NAC S and post-NAC S. Overall survival (OS) analysis using the Cox hazard model showed that stage III (p < 0.01) and post-NAC S (p = 0.03) were poor prognostic factors. Changes in body composition during NAC affected perioperative complications and prognosis of patients with ESCC.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Neoadjuvant chemotherapy with S-1 plus cisplatin for esophageal squamous cell carcinoma
    Takahashi, Takamasa
    Kaneoka, Yuji
    Maeda, Atsuyuki
    Takayama, Yuichi
    Seita, Kazuaki
    UPDATES IN SURGERY, 2022, 74 (02) : 675 - 683
  • [22] Skeletal muscle mass and quality before preoperative chemotherapy influence postoperative long-term outcomes in esophageal squamous cell carcinoma patients
    Ichinohe, Daichi
    Muroya, Takahiro
    Akasaka, Harue
    Hakamada, Kenichi
    WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2023, 15 (04): : 621 - 633
  • [23] Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
    Lv, Huilai
    Tian, Yang
    Li, Jiachen
    Huang, Chao
    Sun, Bokang
    Gai, Chunyue
    Li, Zhenhua
    Tian, Ziqiang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma
    Nguyen Vo Vinh Loc
    Nguyen Lam Vuong
    Lam Viet Trung
    Tran Thien Trung
    Journal of Gastrointestinal Cancer, 2023, 54 : 1240 - 1251
  • [25] Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma
    Matsuda, S.
    Tsubosa, Y.
    Sato, H.
    Takebayashi, K.
    Kawamorita, K.
    Mori, K.
    Niihara, M.
    Tsushima, T.
    Yokota, T.
    Onozawa, Y.
    Yasui, H.
    Takeuchi, H.
    Kitagawa, Y.
    DISEASES OF THE ESOPHAGUS, 2017, 30 (02):
  • [26] Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma
    Yu, Yong-kui
    Meng, Fan-Yu
    Wei, Xiu-feng
    Chen, Xian-kai
    Li, Hao-miao
    Liu, Qi
    Li, Can-jun
    Xie, Hou-nai
    Xu, Lei
    Zhang, Rui-xiang
    Xing, Wenqun
    Li, Yin
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2024, 168 (02)
  • [27] Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer
    Griffin, Oonagh M.
    Duggan, Sinead N.
    Ryan, Ronan
    McDermott, Raymond
    Geoghegan, Justin
    Conlon, Kevin C.
    PANCREATOLOGY, 2019, 19 (06) : 850 - 857
  • [28] Clinical impact of remnant lymphatic invasion on the recurrence of esophageal squamous cell carcinoma after esophagectomy with neoadjuvant chemotherapy
    Okuda, Sho
    Ohuchida, Kenoki
    Shindo, Koji
    Moriyama, Taiki
    Kawata, Jun
    Tamura, Koji
    Sada, Masafumi
    Nagayoshi, Kinuko
    Mizuuchi, Yusuke
    Ikenaga, Naoki
    Nakata, Kohei
    Oda, Yoshinao
    Nakamura, Masafumi
    ONCOLOGY LETTERS, 2022, 24 (04)
  • [29] Survival impact of the number of lymph nodes dissection in patients receiving neoadjuvant chemotherapy for esophageal squamous cell carcinoma
    Jiang, Duo
    Liu, Xian-Ben
    Xing, Wen-Qun
    Chen, Pei-Nan
    Feng, Shao-Kang
    Yan, Sen
    Lerut, Toni
    Sun, Hai-Bo
    DISEASES OF THE ESOPHAGUS, 2023, 36 (05)
  • [30] Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial
    Tang, H.
    Wang, H.
    Fang, Y.
    Zhu, J. Y.
    Yin, J.
    Shen, Y. X.
    Zeng, Z. C.
    Xiang, D. X.
    Hou, Y. Y.
    Du, M.
    Lian, C. H.
    Zhao, Q.
    Jiang, H. J.
    Gong, L.
    Li, Z. G.
    Liu, J.
    Xie, D. Y.
    Li, W. F.
    Chen, C.
    Zheng, B.
    Chen, K. N.
    Dai, L.
    Liao, Y. D.
    Li, K.
    Li, H. C.
    Zhao, N. Q.
    Tan, L. J.
    ANNALS OF ONCOLOGY, 2023, 34 (02) : 163 - 172